Acutus Medical Launches AcQCross Line Extension Compatible with Watchman Delivery System

June 27, 2022—Acutus Medical, Inc. announced the commercial launch of an expanded suite of left heart access products that includes the company’s AcQCross Qx system for use with the TruSeal and FXD delivery system for the Watchman left atrial appendage closure device (Boston Scientific Corporation). AcQCross and its entire line of catheters are commercially available in the United States.

According to the company, the AcQCross transseptal system is engineered with an integrated needle and dilator to reduce the exchanges of wires and needles while trying to achieve the proper angle and location on the septum.

AcQCross’s array of catheters are length-, diameter-, and tip-matched and designed to lock into the hub of commercially available sheaths used in most left heart procedures, including delivery of the Watchman.

“Crossing the septum at the proper location is important when doing any left-sided heart procedure, but it can be especially critical to the success of delivering Watchman to the left atrial appendage,” Tom Waggoner, DO, commented in the company’s press release. Dr. Waggoner, who is Director, Structural Heart Program and Cardiovascular Research, Tucson Medical Center in Tucson, Arizona, continued, “With AcQCross, I can easily reposition without withdrawing or exchanging needles or wires, so its new compatibility with Watchman has made my procedures much safer for my patients and far more efficient for me and my team.”

On April 27, 2022, Acutus announced a definitive agreement to sell its left heart access portfolio to Medtronic. Under the terms of the agreement, Medtronic will make an upfront cash payment to Acutus of $50 million upon the initial closing of the transaction, subject to the satisfaction of customary closing conditions.